GlassScriptPhysician profile
Vinod Trivedi
NPI 1003001645
$2,227.36
in general payments reported to CMS, 2019-2025
25 companies · $60.82 in 2025
The $60.82 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,275 · 2020: $484 · 2021: $150 · 2022: $114 · 2023: $41.07 · 2024: $103 · 2025: $60.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $204.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $752.59 | 2019-2025 | |
| Allergan, INC. | $343.06 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $202.42 | 2019-2022 | |
| Abbvie INC. | $107.54 | 2021-2023 | Avycaz |
| Glaxosmithkline, LLC. | $105.69 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.13 | 2019-2024 | Spiriva Respimat |
| Mayne Pharma Commercial LLC | $61.65 | 2020 | |
| Tetraphase Pharmaceuticals, INC. | $60.85 | 2019 | |
| Janssen Pharmaceuticals, INC | $56.96 | 2021 | |
| Insmed, INC. | $55.61 | 2019 | |
| Amgen INC. | $53.21 | 2024-2025 | Tezspire |
| Paratek Pharmaceuticals, INC. | $51.32 | 2019-2020 | |
| Theratechnologies INC. | $50.53 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $47.18 | 2020-2024 | Austedo Xr |
| Janssen Biotech, INC. | $35.40 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $24.83 | 2025 | Vowst |
| Actelion Pharmaceuticals US, INC. | $24.44 | 2019 | |
| Vyera Pharmaceuticals, LLC | $18.93 | 2019 | |
| Pulmonx Corporation | $18.51 | 2024 | Chartis Catheter, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
| United Therapeutics Corporation | $18.40 | 2019 | |
| Emd Serono, INC. | $16.33 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $16.32 | 2021 | |
| Grifols USA, LLC | $15.74 | 2020 | |
| Advanced Respiratory, INC | $13.40 | 2020 | |
| Optinose US, INC. | $11.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinod Trivedi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.